Sygnis AG - Research Report (Anno) - 18.06.18
SYGNIS AG, headquartered in Heidelberg, is a life sciences company listed on the Prime Standard of the Deutsche Börse. The company focuses on the development and marketing of innovative molecular biology technologies in the NGS (next-generation sequencing) and the immuno-diagnostic sector. Its most important products currently on the market are TruePrimeTM (DNA amplification), SunScriptTM (transcribing RNA into DNA), RunBlue (DNA and protein separation and purification), Lightning Link (DNA and protein labeling) and CaptsureTM (biomarker capture) which are sold both through their own marketing and by nonexclusive sales partners. Other products (e.g., DNA amplification under liquid biopsy) should also make entry possible into high-volume point of care and clinical diagnostic markets (e.g. hospitals). SYGNIS AG acquired Expedeon Holdings Ltd. and C.B.S. Scientific in 2016 as part of its acquisitive growth strategy. This expanded its product spectrum in the proteomics area, the second most important market segment for molecular biology. Innova Bioscience Ltd was acquired in 2017, resulting in further vertical expansion of the product range.
Die GBC AG mit Sitz in Augsburg ist eines der führenden bankenunabhängigen Investmenthäuser in Deutschland und erfahrener Emissionsexperte für den deutschen Mittelstand.
Die GBC AG kennt als eigentümergeführtes Unternehmen die Bedürfnisse des deutschen Mittelstandes im Finanzierungsbereich und ist ein unabhängiger und verlässlicher Partner bei allen Fragestellungen rund um den Kapitalmarkt.
In der GBC Gruppe bietet die GBC AG Unternehmensanalysen & Research, Kapitalmarkt- & Finanzierungsberatungen sowie Kapitalmarktkonferenzen.
Die GBC Kapital GmbH ergänzt die Leistungen in der Gruppe um das Corporate Finance in den Bereichen Platzierung & Vermittlung von Anleihen und Aktien
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.